Form 4: Novavax CEO John Jacobs Reports Stock Transactions
SEC Form 4
Novavax CEO John Jacobs reports the disposition of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On March 1, 2025, John C. Jacobs, the President and CEO of Novavax Inc., reported transactions involving Novavax common stock.
- Jacobs disposed of 38,451 shares of common stock at a price of $8.33 per share to satisfy tax obligations related to the vesting of restricted stock units (RSUs).
- He also exercised 83,334 restricted stock units.
- Following these transactions, Jacobs directly owns 136,732 shares of Novavax common stock and 166,666 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting stock transactions, and it doesn't inherently convey positive or negative sentiment. It's a neutral disclosure.
Industry Context
This is a routine disclosure of stock transactions by a company executive, which is common practice and required by the SEC.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the impact is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 03/01/2025 | Date of stock transactions (exercise of RSUs and disposition of shares). |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.